Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chordia Therapeutics Inc. ( (JP:190A) ) just unveiled an announcement.
Chordia Therapeutics Inc. announced the recording of non-operating income from a grant for a research project on therapeutic agents for tumors with RNA splicing mutations. This grant income, amounting to 30 million yen, will be reflected in the company’s financial results for the first quarter of the fiscal year ending August 31, 2026. The financial impact of this grant has already been accounted for in the company’s business forecast, indicating a stable financial outlook.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a company operating in the biotechnology industry, focusing on the development of novel cancer therapies. Its primary products include rogocekib, a CLK inhibitor currently in Phase 1/2 clinical trials in the US, and other assets like CTX-177, CTX-439, and GCN2 inhibitors. The company collaborates with institutions such as Kyoto University to advance its research.
Average Trading Volume: 805,151
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.37B
See more insights into 190A stock on TipRanks’ Stock Analysis page.